Search

CN-122017258-A - Application of BDNF in prediction of risk of postpartum depression

CN122017258ACN 122017258 ACN122017258 ACN 122017258ACN-122017258-A

Abstract

The invention relates to application of BDNF as a biomarker in prenatal prediction of risk of postnatal depression. The mBDNF and proBDNF levels in cerebrospinal fluid and plasma can be used as independent markers for predicting the risk of postpartum depression, and the plasma mBDNF or the proBDNF level in the cerebrospinal fluid can be used for predicting the risk of postpartum depression through prenatal detection, so that the prediction, early identification and timely intervention of postpartum depression are facilitated, and the harm of postpartum depression is reduced.

Inventors

  • LV MIN
  • ZHANG XIAOBAO
  • WANG XINXIN
  • SHI YUHUI
  • LIU LU

Assignees

  • 江苏省肿瘤医院
  • 连云港市第一人民医院

Dates

Publication Date
20260512
Application Date
20260415

Claims (10)

  1. 1. Use of mBDNF in the preparation of an agent for prenatal prediction of the risk of postnatal depression.
  2. 2. Use of a reagent for the preparation of a kit for prenatal prediction of the risk of developing postnatal depression, wherein the reagent is for determining mBDNF levels in the plasma of a subject.
  3. 3. A kit for prenatal prediction of the risk of developing postnatal depression, wherein the kit comprises reagents for determining mBDNF levels in the plasma of a subject.
  4. 4. The use of claim 2 or the kit of claim 3, wherein the kit determines mBDNF levels in the subject's plasma by ELISA.
  5. 5. The use of claim 2 or the kit of claim 3, wherein the kit determines mBDNF levels in the subject's plasma by a DuoSet ELISA.
  6. 6. Use of probnf for the preparation of a reagent for prenatal prediction of the risk of postnatal depression.
  7. 7. Use of a reagent for the preparation of a kit for prenatal prediction of the risk of developing postnatal depression, wherein the reagent is for determining the level of proBDNF in cerebrospinal fluid of a subject.
  8. 8. A kit for prenatally predicting the risk of developing postnatal depression, wherein the kit comprises reagents for determining the level of probnf in the cerebrospinal fluid of a subject.
  9. 9. The use of claim 7 or the kit of claim 8, wherein the kit determines the level of probnf in the cerebrospinal fluid of the subject by ELISA.
  10. 10. The use of claim 7 or kit of claim 8, wherein the kit determines the level of probnf in the cerebrospinal fluid of the subject by a DuoSet ELISA.

Description

Application of BDNF in prediction of risk of postpartum depression Technical Field The invention belongs to the technical field of molecular diagnosis, and particularly relates to application of BDNF serving as a biomarker in prenatal prediction of risk of postnatal depression. Background Postpartum depression (Postpartum depression, PPD) is often untreated due to hidden and inadequate onset, thereby compromising maternal and mental health, destroying maternal and infant attachment, and deleteriously affecting the cognitive, emotional and behavioral trajectories of offspring. In recent years, abnormal neuroplasticity has been considered as a key central mechanism for depression occurrence, and brain-derived neurotrophic factor (brain-derived neurotrophic factor, BDNF) as a key factor for regulating neuroplasticity, occupies an important position （Qin M, Chen Y, Wang X, et al. Dexmedetomidine induces IL-10 secretion by B lymphocytes in the peripheral blood of patients with hepatocellular carcinoma [J]. Immunobiology, 2024, 229(5): 152842;Park H, Poo MM. Neurotrophin regulation of neural circuit development and function [J]. Nature Reviews Neuroscience, 2012, 14(1): 7-23）. in the pathogenesis of PPD, and besides promoting the growth, differentiation and migration of neurons, BDNF is important for the formation and stabilization of synapses, thereby playing an important role in nervous system functions, learning and memory, and mood regulation （Arancio O, Chao MV. Neurotrophins, synaptic plasticity and dementia [J]. Current Opinion in Neurobiology, 2007, 17(3): 325-30;Lu B, Pang G, Hew NH, et al. New insights into the role of brain-derived neurotrophic factor in synaptic plasticity [J]. Molecular and Cellular Neuroscience, 2009, 42(2): 81-89）. BDNF is involved in the regulation of depression under physiological conditions mainly in two molecules with different activities, precursor brain-derived neurotrophic factor (Precursor brain-derived neurotrophic factor, proBDNF) and Mature brain-derived neurotrophic factor (material brain-derived neurotrophic factor, mBDNF). proBDNF preferentially binds to the p75 neurotrophic factor receptor (p 75 neurotrophin receptor, p75 NTR), promoting apoptosis and synaptic pruning, while mBDNF activates Tropomyosin-receptor-kinase B (TrkB) and downstream cAMP response-element-binding protein (CREB) signals, promoting the growth and development of neural cells. The dynamic balance between ProBDNF and mBDNF controls the homeostasis of the signal conditioning network, and the disruption of this balance may be the pathogenesis of PPD （Castrén E, Rantamäki T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity [J]. Developmental Neurobiology, 2010, 70(5): 289-297;Zhang J, Yao W, Hashimoto K. Brain-derived Neurotrophic Factor (BDNF)-TrkB Signaling in Inflammation-related Depression and Potential Therapeutic Targets [J]. Current Neuropharmacology, 2016, 14(7): 721-731;Singh S, Fereshetyan K, Shorter S, et al. Brain-derived neurotrophic factor (BDNF) in perinatal depression: Side show or pivotal factor [J]. Drug Discovery Today, 2023, 28(2): 1-7）. Most current clinical studies use conventional methods to detect BDNF in blood, and often cannot accurately distinguish between procdnf and mBDNF, which may be one of the reasons for the difference in the results of the study. There has been no study to simultaneously compare the difference in sensitivity of cerebrospinal fluid (CSF) to PPD prediction with peripheral blood BDNF (including its pro BDNF and mBDNF subtypes). Thus, there is an urgent need for prenatal diagnostic markers that have strong predictive power and cost effectiveness to facilitate early discovery and timely intervention of PPD. Disclosure of Invention The present study recruits parturients from a selective caesarean section while quantifying BDNF subtypes in CSF and plasma (proBDNF, mBDNF), systematically evaluating the predictive effect of these biomarkers on PPD pathogenesis. According to the invention, a PPD risk layering model based on multi-mode biomarkers is constructed, and precise intervention in the perinatal period is finally realized. A first aspect of the invention provides a biomarker BDNF that may be used to pre-partum predict the risk of developing postnatal depression. Preferably, BDNF is mBDNF or probnf. Through the creative parting detection of the invention, mBDNF and proBDNF can be found to be used as independent predictors of the risk of postpartum depression. In a preferred embodiment, the biomarker is mBDNF, and the risk of post-natal depression is predicted by detecting mBDNF levels in the plasma of a pregnant woman before delivery, a lower plasma mBDNF level being indicative of a higher risk of post-natal depression. In another preferred embodiment, the biomarker is proBDNF, and the risk of post-natal depression is predicted by detecting proBDNF levels in the cerebrospinal fluid